We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICMRA Examines Artificial Intelligence Risks in Pharmacovigilance
ICMRA Examines Artificial Intelligence Risks in Pharmacovigilance
Artificial intelligence-based software developed to conduct pharmacovigilance “appears suitable for the detection of safety signals,” the International Coalition of Medicines Regulatory Authorities (ICMRA) says in a new report on the use of AI for drug development.